drug_type
RELEVANT_DRUG
intervention_type
Biological: gene-modified cellular immunotherapy
drug_description
Autologous T lymphocytes genetically engineered to express a chimeric antigen receptor targeting tumor-associated antigen(s); administered as a single IV infusion (~1–2×10^6 cells/kg) after fludarabine/cyclophosphamide lymphodepletion to enable expansion and persistence. Mechanism: MHC-independent antigen recognition via CAR with CD3ζ ± costimulatory domains, leading to T-cell activation, cytokine release, and perforin/granzyme-mediated cytotoxic killing.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T lymphocytes are genetically engineered to express a chimeric antigen receptor that binds tumor-associated antigens independent of MHC, delivering CD3ζ signaling with costimulatory domains to activate T cells. Upon antigen engagement, CAR-T cells expand, release cytokines, and kill target cells via perforin/granzyme and apoptotic pathways. Lymphodepleting chemotherapy (fludarabine/cyclophosphamide) enhances CAR-T expansion and persistence after infusion.
drug_name
CAR-T cell therapy
nct_id_drug_ref
NCT06572956